When patients with the HLA-DQ2 gene – approximately 90% of people with celiac disease (ref. 8 ) – undergo a “gluten challenge” by eating gluten in wheat, rye, or barley for three days, T cells specific for gluten appear briefly in blood. (ref. 9, 10). Most of these T cells recognize one of the three peptides in Nexvax2® . This breakthrough has allowed ImmusanT to begin development of targeted immunotherapy for HLA DQ2-associated celiac disease.